21 CFR 520.1284

§ 520.1284 Liothyronine.

United States · 21 CFR — Food and Drugs · Status: effective

Cite this

Citation: 21 CFR 520.1284, § 520.1284 Liothyronine, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87208
Permanent ID: ys:prov:87208@1
SHA-256: 68d1771fb6f7d461464322ffe4bec4846def508963c2f8db417a754f3d0364bb

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

(a) Specifications. Each tablet contains 60 or 120 micrograms (µg) liothyronine as the sodium salt. (b) Sponsor. See No. 054771 in § 510.600(c) of this chapter. (c) Conditions of use in dogs—(1) Amount. Administer orally to dogs at levels up to 12.8 µg per kilogram (/kg) of body weight per day. Dosage should be adjusted according to the severity of the condition and the response of the patient. Dosage at the total replacement level (12.8 µg/kg of body weight) should be considered for initiating therapy and then titrated downward for optimum maintenance effect. Twice daily administration is recommended. (2) Indications for use. For treatment of hypothyroidism in dogs. (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Legislative history

This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.